Anthony J. Muslin
Affiliations: | Washington University, Saint Louis, St. Louis, MO |
Area:
Cell Biology, Molecular BiologyGoogle:
"Anthony Muslin"Parents
Sign in to add mentor| Bradford C. Berk | post-doc | 1986-1987 | Harvard Medical School - BWH |
| Lewis T. Williams | post-doc | 1989-1994 | UCSF School of Medicine (Neurotree) |
Children
Sign in to add trainee| chunlai wu | grad student | Washington University (Neurotree) | |
| Heming Xing | grad student | 2000 | Washington University |
| Tanawat Jirakulaporn | grad student | 2004 | Washington University |
| Brian J. DeBosch | grad student | 2008 | Washington University |
| Jeffrey M. Lau | grad student | 2008 | Washington University |
| Brandon M. Proctor | grad student | 2008 | Washington University |
Collaborators
Sign in to add collaborator| Kendall J. Blumer | collaborator | Washington University School of Medicine (Neurotree) | |
| Andrey S. Shaw | collaborator | 1994-1996 | Washington University School Medicine (Neurotree) |
| Kerry Kornfeld | collaborator | 1995-1998 | Washington University School of Medicine |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Bergougnan L, Andersen G, Plum-Mörschel L, et al. (2020) Endothelial-protective effects of a G-protein-biased S1P agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial. British Journal of Clinical Pharmacology |
| Bergougnan L, Armani S, Golor G, et al. (2020) First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased Sphingosine-1 phosphate receptor-1 agonist for endothelial protection. British Journal of Clinical Pharmacology |
| Poirier B, Briand V, Kadereit D, et al. (2020) A G protein-biased S1P agonist, SAR247799, protects endothelial cells without affecting lymphocyte numbers. Science Signaling. 13 |
| Beauverger P, Ozoux ML, Bégis G, et al. (2019) Reversion of cardiac dysfunction by a novel orally available calcium/calmodulin-dependent protein kinase II inhibitor, RA306, in a genetic model of dilated cardiomyopathy. Cardiovascular Research |
| Villard EF, Thedrez A, Blankenstein J, et al. (2016) PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab. Jacc. Basic to Translational Science. 1: 419-427 |
| Pang P, Jin X, Proctor BM, et al. (2015) RGS4 inhibits angiotensin II signaling and macrophage localization during renal reperfusion injury independent of vasospasm. Kidney International. 87: 771-83 |
| Williams JW, Yau D, Sethakorn N, et al. (2013) RGS3 controls T lymphocyte migration in a model of Th2-mediated airway inflammation. American Journal of Physiology. Lung Cellular and Molecular Physiology. 305: L693-701 |
| Beharier O, Dror S, Levy S, et al. (2012) ZnT-1 protects HL-1 cells from simulated ischemia-reperfusion through activation of Ras-ERK signaling. Journal of Molecular Medicine (Berlin, Germany). 90: 127-38 |
| Sari FR, Widyantoro B, Thandavarayan RA, et al. (2011) Attenuation of CHOP-mediated myocardial apoptosis in pressure-overloaded dominant negative p38α mitogen-activated protein kinase mice. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 27: 487-96 |
| Siedlecki AM, Jin X, Thomas W, et al. (2011) RGS4, a GTPase activator, improves renal function in ischemia-reperfusion injury. Kidney International. 80: 263-71 |